Company name: Sinopsys Surgical, also known as DCS Surgical Inc.
Industry: Medical devices (surgery).
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Location: Boulder, Colorado.
Solution/product: Currently in stealth mode, the company is developing minimally invasive surgical technology for the lacrimal system, which comprises structures for tear production and drainage.
Money raised: Half of a $2.4 million equity offering.
Investors: The U.S. Securities and Exchange Commission filing lists directors from DFJ Mercury, High Country Venture and Aweida Venture Partners.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Management team: CEO Harry Ross is a former partner at Aweida Venture Partners.
Competitors: Quest Medical, FCI Ophthalmics and Sterimedix also make devices for blocked tear ducts.
